1-But-2-enylazetidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 1-But-2-enylazetidine
• 英文别名: 1-[(E)-but-2-enyl]azetidine
• 化学式: C₇H₁₃N
• 分子量: 111.18
• InChiKey: WEFPHRCLYYRWCO-NSCUHMNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  杂氮环丁烷 、 1,3-丁二烯 生成 1-But-2-enylazetidine
  参考文献：
  名称：

  LEDINA L. E.; PERCHENKO V. N.; NAMETKIN N. S.; KRAPIVIN A. M., DOKL. AN CCCP, 1978, 243, HO 5, 1200-1203

  摘要：

  DOI：

文献信息

• [EN] BORONATES AS ARGINASE INHIBITORS<br/>[FR] BORONATES EN TANT QU'INHIBITEURS D'ARGINASE
  申请人：MARS INC

  公开号：WO2012058065A1

  公开（公告）日：2012-05-03

  Compounds according to Formula I are potent inhibitors of Arginase I and II activity: (I) where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.

  根据公式I，化合物是Arginase I和II活性的有效抑制剂：(I)其中R1、R2、R3、R4、D、W、X、Y和Z在说明书中有定义。该发明还提供了这些化合物的药物组合物以及它们在治疗或预防与Arginase活性相关的疾病或病况的方法。
• [EN] INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS<br/>[FR] INHIBITEURS D'ARGINASE ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：MARS INC

  公开号：WO2011133653A1

  公开（公告）日：2011-10-27

  Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity : Formule (I), (II) where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

  根据式I和式II，化合物是Arginase I和II活性的强效抑制剂：式(I)，(II)中的R1、R2、R3、R4、R5、R6、R7、R8、R9、D、M、X和Y的定义如规范所述。该发明还提供了这些化合物的药物组合物以及它们用于治疗或预防与Arginase活性相关的疾病或病况的方法。
• [EN] RNA-FOCUSED SMALL MOLECULES FOR INHIBITING RNA TOXICITY IN MYOTONIC DYSTROPHY<br/>[FR] PETITES MOLÉCULES FOCALISÉES SUR L'ARN POUR INHIBER LA TOXICITÉ DE L'ARN DANS LA DYSTROPHIE MYOTONIQUE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2017049165A1

  公开（公告）日：2017-03-23

  The invention provides compounds and their pharmaceutical compositions according to Formula (I) that are useful for inhibiting RNA toxicity, such as in the treatment of myotonic dystrophy type 1, wherein W1, W2, W3, W4, L1, L2, and Cy are defined herein.

  该发明提供了根据式（I）的化合物及其药物组合物，用于抑制RNA毒性，例如在治疗肌萎缩性脱髓鞘疾病类型1方面，其中W1、W2、W3、W4、L1、L2和Cy在此处被定义。
• LOW PH METAL-FREE PREPARATION OF AMINATED ORGANIC ACID
  申请人：Halliburton Energy Services, Inc.

  公开号：US20160229797A1

  公开（公告）日：2016-08-11

  The invention provides a process for making compounds according to Formula I: where R 1 , R 1a , R 2 , R 2a , R 3 and R 3a are defined as set forth in the specification. Formula I compounds are useful as chelants and stabilizers of cations in aqueous media and the invention therefore provides a method for using the compounds in the treatment of subterranean formations, such as in acidizing operations.

  本发明提供了一种制备公式I化合物的方法：其中，R1、R1a、R2、R2a、R3和R3a的定义如规范中所述。公式I化合物在水介质中作为螯合剂和阳离子稳定剂具有实用价值，因此本发明提供了一种使用该化合物处理地下地层的方法，例如在酸化操作中的应用。
• INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS
  申请人：Van Zandt Michael

  公开号：US20120083469A1

  公开（公告）日：2012-04-05

  Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

  根据公式I和公式II的化合物是Arginase I和II活性的有效抑制剂：其中R1，R2，R3，R4，R5，R6，R7，R8，R9，D，M，X和Y的定义如规范中所述。该发明还提供了这些化合物的制药组合物和使用它们治疗或预防与Arginase活性相关的疾病或病况的方法。